Benmelstobart Injection

Bemosubumab is a new type of humanized IgG1 subtype PD-L1 inhibitor. It directly acts on the PD-L1 receptor on the surface of tumor cells, prevents tumor cells from escaping immune system, and maintains the tumor killing activity of T cells [1]. At the same time, it can block the binding of PD-L1 to B7.1 on the surface of T cells, which helps to fully activate the anti-tumor effect of T cells [1,2].

IgG1 subtype antibodies have good stability, high affinity, strong binding to PD-L1 protein, and can effectively block the PD-L1/PD-1 signaling pathway [3]. Humanization means that the antibody is very similar to the antibodies produced by the human body in structure and function. This design reduces the possible immune response in the patient’s body, thereby improving the reliability of treatment while exerting anti-tumor effects [4,5].

Anlotinib is a small molecule multi-target tyrosine kinase inhibitor that can effectively inhibit kinases such as VEGFR, PDGFR, FGFR, and c-Kit, inhibit tumor angiogenesis, and inhibit tumor growth by cutting off the supply system of tumor cells. At the same time, anlotinib can regulate the tumor immune microenvironment and promote anti-tumor immune response by combining with PD-1/PD-L1 inhibitors [6,7], achieving anti-tumor effects.

The four-drug combination of “bemosubizumab + anlotinib + etoposide + carboplatin” has brought a new breakthrough in the treatment of small cell lung cancer: bemosubizumab activates the human immune system and accurately attacks tumor cells to achieve immune attack; anlotinib effectively inhibits tumor growth by regulating tumor angiogenesis and tumor immune microenvironment; etoposide and carboplatin, as chemotherapy drugs, can directly affect the repair and synthesis of tumor cell DNA, and strongly block its growth and reproduction path. This program combines multiple treatment methods, combining strong methods to achieve a comprehensive attack on tumors, providing patients with more efficient treatment options.